TRAb (Elecsys Anti-TRAb v2, Roche Diagnostics; reference range, <2.0 IU/L), TgAb (Elecsys Anti-Tg, Roche Diagnostics; reference range, <28.0 IU/mL), and TPOAb (Elecsys Anti-TPO, Roche Diagnostics; reference range, <16.0 IU/mL) were measured on a Roche Cobas e801 analyzer (Roche Diagnostics) according to the manufacturer’s instructions. TSH (Elecsys TSH v2, Roche Diagnostics; reference range, 0.500-5.000 μIU/mL), free T4 (FT4, Elecsys FT4III, Roche Diagnostics; reference range, 0.90-1.7 ng/dL), and free T3 (FT3, Elecsys FT3III, Roche Diagnostics; reference range, 2.30-4.00 pg/mL) were measured on a Roche Cobas e801 analyzer (Roche Diagnostics) according to the manufacturer’s instructions. Increases of TRAb, TSH, FT4, and FT3 from baseline to 4 weeks after the third dose were defined as ΔTRAb, ΔTSH, ΔFT4, and ΔFT3, respectively, which were calculated as:
(value at 4 weeks after the third dose) - (value at baseline).
Increases of TgAb and TPOAb from 32 weeks after the second dose (pre-third dose) to 4 weeks after the third dose (post-third dose) were also defined as ΔTgAb and ΔTPOAb, respectively, and calculated as:
(vales at 4 weeks after the third dose) - (values at 32 weeks after the second dose).
Responders to increase in TRAb were defined as the subjects who exhibited increase in TRAb in a time dependent manner and had TRAb >1.2 IU/L at 4 weeks after the third dose.
(value at 4 weeks after the third dose) - (value at baseline).
Increases of TgAb and TPOAb from 32 weeks after the second dose (pre-third dose) to 4 weeks after the third dose (post-third dose) were also defined as ΔTgAb and ΔTPOAb, respectively, and calculated as:
(vales at 4 weeks after the third dose) - (values at 32 weeks after the second dose).
Responders to increase in TRAb were defined as the subjects who exhibited increase in TRAb in a time dependent manner and had TRAb >1.2 IU/L at 4 weeks after the third dose.